Company Presentation

FoRx Therapeutics focuses on the discovery and development of small molecule inhibitors against key proteins involved in the response to oncogene-induced DNA replication stress, which constitutes an innovative approach to identifying novel, targeted anti-cancer drugs. The company has currently 15 employees and is backed by a syndicate of investors that include EQT Life Sciences, Novartis Venture Fund, Pfizer Ventures, Omega Funds and M Ventures.